Regulation of advanced therapies in Europe: Are we on the right track?
- PMID: 37541207
- DOI: 10.1016/j.stem.2023.07.004
Regulation of advanced therapies in Europe: Are we on the right track?
Abstract
Sixteen years after regulating advanced therapy medicinal products (ATMPs) in the European Union, few ATMPs have gained marketing authorization. Additionally, market withdrawals for commercial reasons and a lack of reimbursement are de facto blocking patient access. Here, we pinpoint the major factors underlying this roadblock and how to circumvent it.
Copyright © 2023 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests The authors declare no competing interests.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources